Dupilumab: 15 agencies, 2017–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “For treatment of moderate-to-severe atopic dermatitis.”, while PBAC (Australia) recorded not recommended for “Severe atopic dermatitis”.
CIPM (Spain) has been harder on dupilumab than on its own caseload: it refused 9 of 10 decisive submissions here (90%), against a base rate of 63% across everything it has assessed.
Assessment has run over 8.8 years, from 19 Sep 2017 at AWMSG (Wales) to 7 Jul 2026 at TLV (Sweden).
PBAC (Australia) changed its position: not recommended in 2018, recommended by 2026, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for dupilumab.
Not every gap is a refusal: for dupilumab, 3 submissions were never made and 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 53 of 116 records date from 2023 or later.
The programme is broad: 31 distinct indication wordings are recorded for dupilumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
16 of these 116 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess dupilumab, on 19 Sep 2017; PHARMAC (New Zealand) did not open a file until 24 Jan 2025 — a wide spread of 7.3 years between the earliest and latest system to look at it.
The record arrives in waves: 9 separate years each carry two or more decisions, spread across 10 years in total.
Restriction is doing real work here: 25 of 91 decisive outcomes narrowed dupilumab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), AWMSG (Wales) and DMC (Denmark) among others.
14 of the 15 agencies here assessed dupilumab more than once, PBAC (Australia) most often at 16 entries — repeat review is the norm for this molecule rather than the exception.
dupilumab has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for dupilumab reads 45 recommended, 25 restricted, 21 not recommended and 6 no benefit, with 19 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Chronic severe atopic dermatitis | Not Recommended | source |
| SMC (Scotland) | 8 Jun 2026 | As an add-on therapy with intranasal corticosteroids (INCS) for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy … | accepted (restricted) | source |
| AOTMIT (Poland) | 26 May 2026 | programu lekowego „Leczenie chorych z przewlekłą obturacyjną chorobą płuc (POChP) (ICD-10: J44) | not recommended | source |
| NYE METODER (Norway) | 26 Apr 2026 | Til voksne som tilleggsvedlikeholdsbehandling ved ukontrollert kronisk obstruktiv lungesykdom (KOLS) karakterisert ved f… | not introduced | source |
| CIPM (Spain) | 24 Apr 2024 | Indicación terapéutica autorizada y financiada: Indicaciones terapéuticas autorizadas: Dermatitis atópica - Adultos y ad… | financed by the SNS · art. 92 a, c | source |
111 further decisions for dupilumab, across 15 agencies, are not shown here. They include the most recent record on file, 7 Jul 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 83 further source documents.
Related molecules
- abrocitinib — same ATC class D11A — Other dermatologicals
- nemolizumab — same ATC class D11A — Other dermatologicals
- lebrikizumab — same ATC class D11A — Other dermatologicals
- delgocitinib — same ATC class D11A — Other dermatologicals
- diclofenac — same ATC class D11A — Other dermatologicals
- ivermectin — same ATC class D11A — Other dermatologicals
Coverage: 116 decisions for dupilumab from 15 agencies, 2017 to 2026. Data to 7 Sep 2026. ATC class D11A — Other dermatologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.